Not recruiting
B-cell lymphoma+1
Not recruitingStudy on the Safety and Effects of Englumafusp Alfa with Obinutuzumab and Glofitamab for Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Registered drugNo placebo
Study on the Safety and Effects of Englumafusp Alfa with Obinutuzumab and Glofitamab for Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Registered drugNo placebo
- Disease:B-cell lymphomaB-cell lymphoma refractory
- Substances:Englumafusp AlfaGlofitamab+2
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Englumafusp Alfa



